Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab and LYMPHIR in Cancer Patients with Recurrent Solid Tumors
| CTOR Stock | 0.94 0.06 6.00% |
Slightly above 61% of Citius Oncology,'s investor base is looking to short. The analysis of overall sentiment of trading Citius Oncology, stock suggests that many investors are alarmed at this time. Citius Oncology,'s investing sentiment overview a quick insight into current market opportunities from investing in Citius Oncology,. Many technical investors use Citius Oncology, stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Citius |
PRNewswire -- Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. ,...
Read at prnewswire.com
 |
Citius Oncology, Fundamental Analysis
We analyze Citius Oncology,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Citius Oncology, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Citius Oncology, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Citius Oncology, is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Citius Oncology, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Citius Oncology, stock to make a market-neutral strategy. Peer analysis of Citius Oncology, could also be used in its relative valuation, which is a method of valuing Citius Oncology, by comparing valuation metrics with similar companies.
Peers
Citius Oncology, Related Equities
| PROC | Procaps Group | 53.68 | ||||
| EOLS | Evolus | 7.56 | ||||
| AMPH | Amphastar | 2.24 | ||||
| PBH | Prestige Brand | 1.19 | ||||
| ALKS | Alkermes Plc | 0.24 | ||||
| ITCI | Intracellular | 0.19 | ||||
| PAHC | Phibro Animal | 0.59 | ||||
| PCRX | Pacira BioSciences, | 0.83 |
Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.